Loading clinical trials...
Loading clinical trials...
A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy
Conditions
Interventions
Iptacopan
Locations
48
United States
USC Norris Cancer Center
Los Angeles, California, United States
Univ of California at Los Angeles
Los Angeles, California, United States
Univ Cali Irvine ALS Neuromuscular
Orange, California, United States
Univ of California at Sacramento
Sacramento, California, United States
Harbor-UCLA Medical Center .
Torrance, California, United States
Georgetown University Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Start Date
January 17, 2022
Primary Completion Date
July 9, 2026
Completion Date
August 13, 2026
Last Updated
April 1, 2026
NCT07308574
NCT06312644
NCT05996731
NCT05805202
NCT06065852
NCT05684159
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions